Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants Journal Article


Authors: Davies, S. M.; Wang, D.; Wang, T.; Arora, M.; Ringden, O.; Anasetti, C.; Pavletic, S.; Casper, J.; MacMillan, M. L.; Sanders, J.; Wall, D.; Kernan, N. A.
Article Title: Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants
Abstract: Unrelated donor (URD) bone marrow transplantation (BMT) is an effective treatment for leukemia in children, but its success is threatened by graft-versus-host disease (GVHD) and relapse. In this report, we describe the incidence of and risk factors for GVHD over time in children receiving URD BMT. We analyzed outcomes of 638 myeloablative URD BMTs performed between 1990 and 2003 to treat acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia, or myelodysplastic syndrome MDS, using the Center for International Blood and Marrow Transplant Research (CIBMTR) database. All recipients were under age 18 years and had available high-resolution HLA typing for HLA-A, -B, -C, and -DRB1. Overall, 27% of the recipients developed acute GVHD (aGVHD) grade III-IV; the risk was significantly higher in children receiving T cell-replete grafts compared with those receiving T cell-depleted grafts (odds ratio [OR] = 3.12; 95% confidence interval [CI] = 2.02 to 4.83; P < .0001). Acute GVHD significantly reduced the risk of relapse in children with ALL (OR = 0.34; 95% CI = 0.13 to 0.86; P = .0052), but not in those with AML (OR = 0.58; 95% CI = 0.22 to 2.98; P = .26). The risk of aGVHD was higher in children undergoing transplantation in 1990-1998 (n = 365) compared with those doing so in 1999-2003 (OR = 1.93; 95% CI = 1.27 to 2.91; P = .002). We conclude that outcomes have changed significantly over time, with a reduced risk of aGVHD associated with the more recent transplantations. © 2009 American Society for Blood and Marrow Transplantation.
Keywords: adolescent; child; controlled study; treatment outcome; child, preschool; disease-free survival; leukemia; retrospective studies; acute granulocytic leukemia; major clinical study; busulfan; cytarabine; methotrexate; etoposide; incidence; risk factors; recurrence; cyclophosphamide; hematopoietic stem cell transplantation; chronic myeloid leukemia; retrospective study; risk factor; thiotepa; acute lymphoblastic leukemia; risk assessment; acute graft versus host disease; disease severity; myeloablative conditioning; myelodysplastic syndrome; whole body radiation; tissue donors; infant; hla dr antigen; outcomes research; multivariate analysis; t cell depletion; children; gvhd; unrelated donor transplantation; calcineurin inhibitor; cyclosporin a; hla a antigen; hla b antigen; hla c antigen; tacrolimus; bone marrow transplantation; childhood leukemia; donor selection; hla typing; leukemia relapse; risk reduction; trend study; graft vs host disease
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 15
Issue: 3
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2009-03-01
Start Page: 360
End Page: 366
Language: English
DOI: 10.1016/j.bbmt.2008.12.495
PUBMED: 19203727
PROVIDER: scopus
PMCID: PMC3365559
DOI/URL:
Notes: --- - "Cited By (since 1996): 5" - "Export Date: 30 November 2010" - "CODEN: BBMTF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nancy Kernan
    512 Kernan